<DOC>
	<DOC>NCT01852019</DOC>
	<brief_summary>To demonstrate that patients treated with cangrelor can be directly switched to oral prasugrel and that patients treated with prasugrel can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.</brief_summary>
	<brief_title>Cangrelor Prasugrel Transition Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Cangrelor</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>1. greater than / equal to 18 and less than 75 years of age 2. stable coronary artery disease defined by the following criteria 1. Previous myocardial infarction defined by admission to the hospital with elevation of markers of injury or the presence of pathologic Q waves on at least 2 contiguous electrocardiogram (ECG) leads. OR 2. Previous revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG). AND 3. Treatment with aspirin (ASA) 81 mg daily.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>CAD</keyword>
</DOC>